SecBot SecBot
SECBOTREPLAY Home › Report › CRL

CRL · Charles River Laboratories announced it has entered definitive…

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 8-K filed Nov 9, 2026 at 06:13 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 9, 2026 at 06:13 ET

Charles River Laboratories announced it has entered definitive agreements to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470 million in cash, plus up to $75 million in contingent earnout payments. The transaction is expected to close in the first half of 2027 and is expected to be neutral to non-GAAP EPS in 2027 and accretive thereafter.

  • Purchase price of approximately $470 million in cash for Frontage's bioanalysis and DMPK operations
  • Additional contingent payments of up to $75 million based on future performance
  • Transaction expected to close during first half of 2027
  • Acquired businesses represented approximately 40% of Frontage's total 2025 revenue of $256.7 million

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access